| Field | Specification |
|---|---|
| Target | |
| Alternative names | CpG 1826 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Purity | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
ODN 1826 is a class B CpG oligodeoxynucleotide (ODN) that acts as a TLR9 agonist. It induces NO and iNOS production and enhances apoptosis, boosts immune surveillance, and increases aortic atherosclerotic plaque size; it has also shown antitumor activity against lung cancer, glioma, and melanoma[1][2][3][4][5][6]. Also known as CpG 1826, it is supplied as a white to off-white solid (MW 6364.10) at 97.30% purity.
Physical & Chemical Properties
| CAS Number | 202668-42-6 |
|---|---|
| Molecular Weight | 6364.10 g/mol |
| Purity | 97.30% |
| Appearance | Solid |
| Color | White to off-white |
| Sequence | DNA, d(P-thio)(T-C-C-A-T-G-A-C-G-T-T-C-C-T-G-A-C-G-T-T) |
| Target | TLR9 |
| Signaling Pathway | Immunology/Inflammation; Apoptosis |
| Solubility | In Vitro: H2O: 50 mg/mL (7.86 mM; Requires sonication) |
| Storage | -20°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| H2O | 50 mg/mL (7.86 mM) | requires sonication |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
Data provided by the manufacturer.
In Vitro
In RAW 264.7 mouse macrophages, ODN 1826 (1 μg/mL; 24 h) induces production of nitric oxide (NO) and inducible nitric oxide synthase (iNOS)[3].
In Vivo
Intratumoral injection of CpG-1826 (100 μg/tumor) every 3 days for up to 4 times slows the growth of subcutaneously implanted GL261 gliomas in C57BL/6NTac mice, with increased infiltration of macrophages and B cells into the tumors and significant growth delay in ~50% of mice[4]. In a chronic vascular injury mouse model, 18 nM ODN 1826 given s.c. 3 times a week for 7 weeks enlarges aortic atherosclerotic plaques[5]. In a Lewis lung cancer mouse tumor model, ODN 1826 (0.05 mg i.p. on days 1, 3, 5, 8, 11, 13) exerts a strong anti-tumor growth effect[6].
| Animal Model | 6-week-old male C57BL/6NTac mice; GL261 glioma or B16F10 melanoma subcutaneously implanted in posterior flanks[4]. |
|---|---|
| Dosage | 100 μg/tumor |
| Administration | Intratumoral injection; every 3 days for up to 4 treatments |
| Result | Slowed tumor growth, increased F4/80+ macrophages and B220+ B cells in tumors, with variable responses (50% mice showed prolonged stasis) (in GL261 glioma model). Achieved complete tumor regression and induced long-term immune memory in combination with Cyclophosphamide. Delayed growth but did not induce regression, with modest increases in F4/80+ macrophages and B220+ B cells in combination with Cyclophosphamide (in B16F10 melanoma model). |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
A metabolic alarmin from keratinocytes potentiates systemic humoral immunity. Nature 2026 Apr;652(8108):209-219. PMID: 41781621
A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors. Exploration 2025 Dec 18;5(6):20240396. PMID: 41476656
A Synergistic 3D-Printed Collar Transforms Radiofrequency Ablation Into Potent Thermal Immunotherapy for Lung Cancer. Adv Mater 2025 Sep 1:e02375. PMID: 40891114
GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses. Hepatology 2025 Nov 7. PMID: 41201153
Engineering polymeric RNA scaffolds as programmable combinatorial innate immune agonists. Nucleic Acids Res 2026 Apr 13;54(7):gkag328. PMID: 41978258
Nano Today. 2025 Oct.
Therapeutic Effects of PEG-Modified Polyamide Amine Dendrimer for Cell Free DNA Adsorption in Temporomandibular Joint Osteoarthritis. ACS Appl Mater Interfaces 2024 Jul 31;16(30):39153-39164. PMID: 39018481
CpG-mediated TLR9 signaling pathway enhances the efficacy of the OprF/PcrV DNA vaccine with cGAS-STING-activating properties. Life Sci 2025 Nov 1:380:123930. PMID: 40886938
Dual Targeting of TLR9 and cGAS-STING Pathways Attenuates Astrocyte Inflammatory Activation: Potential Implication in Multiple Sclerosis. Neurochem Res 2025 Sep 5;50(5):288. PMID: 40911109
Interleukin-1 Receptor-Associated Kinase 3 Attenuates Chondrocyte Senescence and Osteoarthritis via Inhibition of the TLR7/9-NF-κB Axis. J Mol Histol 2026 Apr 24;57(3):148. PMID: 42029757
